

Haematologica
HAEMATOL/2014/120790
Version 3

Impact of maintenance therapy on subsequent treatment in patients
with newly diagnosed multiple myeloma: use of "progression-free
survival 2" as a clinical trial end-point

Disclosures: MAD was a consultant for, and received honoraria from, Celgene Corporation. MTP received honoraria from Celgene Corporation and Janssen-Cilag, and served on the advisory committee for Bristol-Myers Squibb. RF is an advisory board member and received honoraria from Celgene Corporation. JC was an advisory board member of and received personal fees, including service on the speakers bureau, from Celgene Corporation. MK is a member of an advisory committee for Celgene Corporation and Ortho Biotech, is on the speakers bureau of Janssen-Cilag, and received honoraria from Celgene Corporation. ET received honoraria from Celgene Corporation. JZ, LG, and CJ are Celgene Corporation employees. AP was a consultant for, and received honoraria from, Amgen, Bristol-Myers Squibb, Celgene Corporation, Janssen-Cilag, Millennium, and Onyx.

Contributions: MAD and AP conceived and designed the study; MTP, RF, JC, MK, ET, JZ, LG, and CJ collected and assembled the data; MAD, ET, JZ, LG, and CJ analyzed and interpreted the data; MTP and JC provided study material or patients; all authors contributed to the writing of the manuscript and gave final approval.